December 12, 2024 21:01 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
UP teenager kills mother, lives with body for 5 days | At least six people including a child killed in Tamil Nadu hospital fire | Amid Atul Subhash row, SC says mere harassment is not enough to prove abetment to suicide | India's D Gukesh becomes youngest ever world champion in chess | Devendra Fadnavis meets PM Modi amid suspense over Maharashtra portfolio allocation | Congress wants to deviate the issue of Sonia Gandhi-George Soros link: JP Nadda | Bengaluru techie suicide: Atul Subhash's family demanded Rs. 10 lakh as dowry leading to my father's death, claims estranged wife | Syria rebels torch tomb of ousted president Bashar al-Assad's father | Donald Trump vows to eliminate birthright citizenship after taking charge | No alliance with Congress in Delhi polls: AAP chief Arvind Kejriwal
Photo Courtesy: Pixabay

Deepak Parekh-backed Nephro Care India Ltd to raise around Rs 40 cr through its IPO on NSE Emerge

| @indiablooms | Jun 22, 2024, at 02:40 am

Kolkata: Deepak Parekh-backed multi-speciality healthcare provider in East India, Nephro Care India Limited (NCIL) is likely to raise around Rs 40 crore through the initial public offering (IPO) to fund its expansion plans.

The company plans to utilise a portion of the net proceeds from the IPO to set up a 100-bedded multispeciality hospital called Vivacity Multi Specialty Hospital at Madhyamgram in Kolkata, West Bengal and the remaining for general corporate purposes.

The IPO is set to open shortly.

The hospital will be a unit of Nephro Care India and is proposed to include 100 inpatient beds, including a 30-bed Critical Care unit having ICU, HDU, RTU and NICU facilities.

Vivacity will offer treatment services in various disciplines such as cardiology, medical oncology, gastroenterology, gynaecology and many others, including an advanced renal transplant unit in East India.

In December 2023, Nephro Care India successfully closed the pre-IPO funding round, which saw the participation of banking veteran and former chairman of HDFC Ltd, Deepak Parekh, Chairman of HDFC Securities Bharat Shah, and Rajendra Agarwal, Founder and MD of Macleods Pharmaceuticals, among others.

Nephro Care was founded in the year 2014 by one of the leading nephrologists in India, Dr. Pratim Sengupta, in Kolkata, with the objective of providing comprehensive medical services for renal patients.

With over 20 years of active clinical experience, Dr. Sengupta, has successfully performed more than 1,000 kidney transplants till now and is a pioneer in holistic renal care through a combination of clinical intervention, yoga and lifestyle support.

Dr. Sengupta has been awarded the “Bharat Jyoti Award” for meritorious services, outstanding achievement and remarkable role by the India International Friendship Society in 2019.

Key Highlights of the IPO

Fresh Issuance: The IPO will comprise a fresh issuance of 45.84 lakh equity shares with a face value of Rs 10 each.

Book Running Lead Manager: Corporate Capital Ventures Private Limited is the Book Running Lead Manager and Bigshare Services Private Limited is the Registrar to the offer. Corporate Capital Ventures Private Limited completed a string of successful SME IPOs in recent past, including Trust Fintech, Creative Graphics, Alpex Solar, Esconet Technologies, Rockingdeals, Accent Microcell, Oriana Power, Droneacharya and Crayons Advertising, among others.

Financial Performance: NCIL posted a revenue of Rs. 19.90 crore and earned a profit (PAT) of Rs. 3.4 crore during the first nine months of FY 2023-24, compared to a revenue of Rs.17.09 crore, with a profit (PAT) of Rs. 1.94 crore in FY 2022-23.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.